Genzyme Corp. (Nasdaq: GENZ) has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath®/MabCampath® (alemtuzumab), giving Genzyme primary responsibility for the development and commercialization of this promising multiple sclerosis (MS) therapeutic candidate. Genzyme is conducting two rapidly progressing phase 3 studies of alemtuzumab in relapsing-remitting MS patients.

AstraZeneca and Merck & Co., Inc. will collaboration to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 (ARRY-886*) from AstraZeneca. Preclinical evidence indicates that combined administration of these compounds could enhance their anticancer properties.

Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.

Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.

Abbott was recently named one of the Top 10 companies on The Scientist magazine's "Best Places to Work in Industry" list. Abbott was ranked No. 6 on the list of Large Companies (more than 5,000 employees). This is the sixth time that Abbott has been on the list since The Scientist first started ranking companies in 2003. This prestigious list is based on a detailed survey of scientists at life-science companies and research institutions worldwide.

AstraZeneca today announced that the company has referred its application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of recurrent depressive episodes in adult patients with major depressive disorder (MDD) to the Committee for Medicinal Products for Human Use (CHMP; a scientific committee of the European Medicines Agency, EMEA).

Bayer HealthCare AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Roche announced the initiation of a Phase III trial examining Nexavar® (sorafenib) tablets in combination with Tarceva® (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.